{"id":157279,"date":"2022-04-27T02:21:00","date_gmt":"2022-04-27T06:21:00","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/pds-biotechnology-co-nasdaqpdsb-given-consensus-recommendation-of-buy-by-analysts-defense-world\/"},"modified":"2024-08-17T16:14:15","modified_gmt":"2024-08-17T20:14:15","slug":"pds-biotechnology-co-nasdaqpdsb-given-consensus-recommendation-of-buy-by-analysts-defense-world","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/pds-biotechnology-co-nasdaqpdsb-given-consensus-recommendation-of-buy-by-analysts-defense-world.php","title":{"rendered":"PDS Biotechnology Co. (NASDAQ:PDSB) Given Consensus Recommendation of Buy by Analysts – Defense World"},"content":{"rendered":"

PDS Biotechnology Co. (NASDAQ:PDSB Get Rating) has been given a consensus rating of Buy by the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $21.20. <\/p>\n

Separately, StockNews.com upgraded shares of PDS Biotechnology to a sell rating in a research report on Saturday, April 9th.<\/p>\n

NASDAQ:PDSB opened at $5.16 on Monday. The firms 50 day simple moving average is $5.95 and its 200 day simple moving average is $7.99. PDS Biotechnology has a one year low of $4.10 and a one year high of $17.85. <\/p>\n

Large investors have recently added to or reduced their stakes in the company. Voloridge Investment Management LLC increased its stake in shares of PDS Biotechnology by 279.2% in the 3rd quarter. Voloridge Investment Management LLC now owns 49,191 shares of the companys stock valued at $733,000 after acquiring an additional 36,219 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of PDS Biotechnology in the 3rd quarter valued at $632,000. Cubist Systematic Strategies LLC increased its stake in shares of PDS Biotechnology by 187.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 71,618 shares of the companys stock valued at $1,067,000 after acquiring an additional 46,665 shares in the last quarter. Jump Financial LLC bought a new stake in shares of PDS Biotechnology in the 3rd quarter valued at $393,000. Finally, Valeo Financial Advisors LLC increased its stake in shares of PDS Biotechnology by 35.7% in the 4th quarter. Valeo Financial Advisors LLC now owns 21,570 shares of the companys stock valued at $175,000 after acquiring an additional 5,670 shares in the last quarter. Institutional investors own 23.91% of the companys stock. <\/p>\n

PDS Biotechnology Company Profile (Get Rating)<\/p>\n

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent\/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.<\/p>\n

Featured Stories<\/p>\n<\/p>\n

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.<\/p>\n

<\/p>\n

Read more:
\nPDS Biotechnology Co. (NASDAQ:PDSB) Given Consensus Recommendation of Buy by Analysts - Defense World<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

PDS Biotechnology Co. (NASDAQ:PDSB Get Rating) has been given a consensus rating of Buy by the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-157279","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/157279"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=157279"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/157279\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=157279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=157279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=157279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}